Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes

References

• Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314: 1360–1368
   PubMed Web of Science ®Google Scholar
• Akerblom HK, Knip M. Putative environmental factor in type 1 diabetes. Diabetes Metab Rev 1998; 14: 31–67
   PubMed Web of Science ®Google Scholar
• Knip M, Akerblom HK. Environmental factors in the pathogenesis of type1 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107(Suppl 3)S93–S100
   PubMedGoogle Scholar
• Hyoty H, Taylor KW. The role of viruses in human diabetes. Diabetologia 2002; 45: 1353–1361
   PubMed Web of Science ®Google Scholar
• Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, et al. Association between rotavirus infection and pancreatic isletautoimmunity in children at risk of developing type 1 diabetes. Diabetes 2000; 49: 1319–1324
   PubMed Web of Science ®Google Scholar
• Díaz-Horta O, Bello M, Cabrera-Rode E, Suárez J, Más P, García I, et al. Echovirus 4 and type 1 diabetes mellitus. Autoimmunity 2001; 34: 275–281
   PubMedGoogle Scholar
• Cabrera-Rode E, Sarmiento L, Tiberti C, Molina G, Barrios J, Hernández D, et al. Type 1 diabetes islet associated antibodies in subjects infected by echovirus 16. Diabetologia 2003; 46: 1348–1353
   PubMed Web of Science ®Google Scholar
• Rønningen KS, Keiding N, Green A, on behalf of genomic marker contributorsand the EURODIAB ACA study group. Correlations between the incidence of childhood-onset type 1 diabetes in Europe and HLA genotypes. Diabetologia 2001; 44(Suppl 3)B51–B59
   Google Scholar
• Kulmala P, Savola K, Reijonen H, Veijola R, Vähäsalo P, Karjalainen J, et al. Genetic markers, humoral autoimmunity, and prediction of type 1 diabetes in siblings of affected children. Childhood diabetes in finland study group. Diabetes 2000; 49: 48–58
   PubMedGoogle Scholar
• Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 103–108
   PubMed Web of Science ®Google Scholar
• Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53: 384–392
   PubMed Web of Science ®Google Scholar
• Colman PG, McNair P, Margetts H, Schmidli RS, Werther GA, Alford FP, et al. The Melbourne pre-diabetes study: Prediction of type 1 diabetes mellitus using antibody and metabolic testing. Med J Aust 1998; 169: 81–84
   PubMedGoogle Scholar
• Elliott RB, Chase HP. Prevention or delay of type (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34: 362–365
   PubMed Web of Science ®Google Scholar
• Elliott RB, Pilcher CC, Fergursson DM, Steward AW. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996; 9: 501–509
   PubMed Web of Science ®Google Scholar
• The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Intervening before the onset of type 1 diabetes: Baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia 2003; 46: 339–346
   PubMedGoogle Scholar
• Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925–931
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care 1996; 19: 1357–1363
   PubMedGoogle Scholar
• Knip M, Douek IF, Moore WPT, Gillmor HA, McLean AE, Bingley PJ, et al. Safety of high-dose nicotinamide: A review. Diabetologia 2000; 43: 1337–1345
   PubMed Web of Science ®Google Scholar
• Crino A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, et al. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol 2004; 150: 719–724
   PubMedGoogle Scholar
• WHO. Diabetes mellitus: Report of a WHO study group. World Health Organization, Geneva 1985
   Google Scholar
• Center for Research and Development of Medications (CIDEM). A report on standardization of a method for determination of N-methyl nicotinamide in urine. CIDEM, Havana 1996
   Google Scholar
• Trinder P. Determination of glucose oxidase with one alternative oxygen acceptor. Ann Clin Biochem 1969; 6: 24–27
   Google Scholar
• Arranz C, González-Suárez RM. Insulin radioimmunoassay: A rapid method for separation of free and bound hormone. Rev Cubana Invest Biomed 1988; 7: 150–156
   Google Scholar
• Matthews DR, Hosker JP, Rudenki AS, Nailor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Bingley PJ, Colman PG, Eisenbarth GS, Jackson RA, McCulloch DK, Riley WJ, et al. Standardization of IVGTT to predict IDDM. Diabetes Care 1992; 15: 1313–1316
   PubMed Web of Science ®Google Scholar
• Vardi P, Dib SA, Tuttleman M, Connelly JE, Grinbergs M, Radizabeh A, et al. Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type 1 diabetes mellitus. Diabetes 1987; 36: 1286–1291
   PubMed Web of Science ®Google Scholar
• Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37: 344–350
   PubMed Web of Science ®Google Scholar
• Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial islet autoantibody workshop. Diabetes 1998; 47: 1857–1866
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Bernoco D, Parks MS, Oztruk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -DR antigens. Am J Clin Pathol 1978; 69: 103–120
   PubMed Web of Science ®Google Scholar
• Bruning JW, Douglas R, Scholtus M, Van Rood JJ. Automatic reading and recording of the microlymphocytotoxicity test. Tissue antigens 1972; 2: 473–477
   PubMedGoogle Scholar
• Böyum A. Separation of leukocyte from blood and bone marrow. Scand J Clin Lab Invest 1968; 21(Suppl)7–97
   Google Scholar
• Mandrup-Poulsen T, Reimers JI, Andersen HU, Pociot F, Karlsen AE, Bjerre U. Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1993; 9: 295–309
   PubMedGoogle Scholar
• Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 1995; 44: 152–155
   PubMed Web of Science ®Google Scholar
• Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Blackwell Scientific Publication, Oxford 1987; 35–53
   Google Scholar
• LaGasse JM, Brantley MS, Leech NJ, Rowe RE, Monks S, Palmer JP, et al. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: An 8-year follow-up of the Washington state diabetes prediction study. Diabetes Care 2002; 25: 505–511
   PubMedGoogle Scholar
• Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes. N Engl J Med 2002; 346: 1685–1691
   PubMed Web of Science ®Google Scholar
• Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol 1998; 35: 61–64
   PubMedGoogle Scholar
• Vidal J, Fernández-Balsells M, Sesmilo G, Aguilera E, Casamitjana R, Gomis R. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 2000; 23: 360–364
   PubMedGoogle Scholar
• Manna R, Migliore A, Martin LS, Ferrara E, Ponte E, Marietti G, et al. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br J Clin Pract 1992; 46: 177–179
   PubMedGoogle Scholar
• Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, et al. The deutsche nicotinamide intervention study: An attempt to prevent type 1 diabetes. Diabetes 1998; 47: 980–984
   PubMed Web of Science ®Google Scholar
• Beales PE, Burr LA, Webb GP, Mansfield KJ, Pozzilli P. Diet can influence the ability of nicotinamide to prevent diabetes in non-obese diabetic mouse: A preliminary study. Diabetes Metab Res Rev 1999; 15: 21–28
   PubMedGoogle Scholar
• Virtanen SM, Knip M. Nutritional risk predictors of β cell autoimmunity and type 1 diabetes at a young age. Am J Clin Nutr 2003; 78: 1053–1067
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481–490
   PubMed Web of Science ®Google Scholar
• Krause I, Tomer I, Elias D, Blank M, Gilburg B, Cohen IR, et al. Inhibition of diabetes in NOD mice by idiotypic induction of SLE. J Autoimmun 1999; 13: 49–55
   PubMedGoogle Scholar
• Binley PJ, Caldas G, Bonfanti R, Gale EA. Nicotinamide and insulin secretion in normal subjects. Diabetologia 1993; 36: 675–677
   PubMedGoogle Scholar
• Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 1996; 45: 1631–1634
   PubMedGoogle Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The diabetes prevention trial-type 1. Diabetes Care 2005; 28: 1068–1076
   PubMed Web of Science ®Google Scholar
• Rossini AA. From beast to bedside: A commentary. Diabetologia 2004; 47: 1647–1649
   PubMedGoogle Scholar
• Devendra D, Liu E, Eisenbarth ES. Type 1 diabetes: Recent developments. BMJ 2004; 328: 750–754
   PubMed Web of Science ®Google Scholar